Antibiotic Resistance of Acinetobacter baumannii in Iran: A Systemic Review of the Published Literature

Jale Moradi, Farhad B. Hashemi, Abbas Bahador*

Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Abstract
Objectives: Acinetobacter baumannii is a bacterium responsible for health care-associated infections, and it frequently develops multiple drug resistance (MDR). The prevalence of antibiotic-resistant A. baumannii in Iran has increased, and this may cause significant clinical problems. Therefore, in order to elucidate the development of antibiotic resistance, we performed a systematic review of the literature published on antibiotic-resistant A. baumannii reported in Iran.

Methods: Thirty-six publications that met the criteria for inclusion were reviewed from an initial 87 papers. Selected papers published between 2008 and September 2014, were categorized on the basis of the sample collecting year been between 2001 and 2013.

Results: Analysis of data revealed that, in general, there was an increase in antimicrobial resistance. During the initial time point of these studies (2001–2007) there was a high rate of resistance to all antibiotics, with the exception of carbapenems, lipopeptides, and aminoglycosides that had a low resistance rate in comparison with the others. Also, the resistance rate was increased in one group of these three antimicrobial groups from 2010 to 2013. In particular, there was an increase in resistance to carbapenems (imipenem and meropenem) from 2010–2011 and 2012–2013, whereas no significant change in the resistance rate of the other two antimicrobial groups (lipopeptides and aminoglycosides) during the study time was observed, although we did observe certain trends in amikacin (aminoglycoside group antibiotic) between 2011–2012 and 2012–2013.

Conclusion: These findings indicate that antimicrobial resistance of A. baumannii in Iran has increased, which may very well affect the antimicrobial resistance of this organism worldwide. Based on these results, novel prevention and treatment strategies against A. baumannii infections are warranted. Furthermore, these data may assist in revising treatment guidelines and regional policies in care units to slow the emergence of antimicrobial resistance.

*Corresponding author.
E-mail: abahador@tums.ac.ir, ab.bahador@gmail.com (A. Bahador).

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © 2015 Korea Centers for Disease Control and Prevention. Published by Elsevier Korea LLC. All rights reserved.
1. Introduction

*Acinetobacter baumannii* is a gram-negative, strictly aerobic, nonfermenting cocccobacillus belonging to the Moraxellaceae family [1]. Species belonging to this genus are opportunistic pathogens with increasing relevance in both community-acquired and nosocomial infections, particularly among patients in intensive care units (ICUs) and high-dependency units (HDUs) [2–5]. These organisms have been implicated in various infections, including ventilator-associated pneumonia, endocarditis, meningitis, and infections of the skin, soft tissues, urinary tract, and those originating from prosthetic devices [4,6]. *A. baumannii* has been isolated from numerous sources such as soil, water, animals, and humans, while its presence in health care institutions and on environmental surfaces has been extremely difficult to control [6].

Three decades ago, *A. baumannii* infections were effectively treated with traditional antibiotics [7,8]. By contrast, it currently exerts resistance to nearly all major classes of antibiotics, including broad-spectrum penicillins, cephalosporins, carbapenems, most aminoglycosides, fluoroquinolones, chloramphenicol, and tetracyclines. In the past decade, multidrug resistant (MDR) clinical isolates have shown global distribution [3]. Therefore, this pathogen has become a “red-alert” for the following reasons: rapid emergence of resistance, increased incidence, and the worldwide spread of MDR isolates [7]. The rapid spread of MDR strains in nosocomial infections that exhibit resistance to most or all common antibiotics is a troubling evolution [3]. Thus, a study of the antibiotic resistance patterns both in individual hospitals and on countrywide levels may help to clarify the mode of *A. baumannii* antibiotic resistance spread and epidemiology worldwide [9]. The current review was performed to elucidate the mode of antibiotic resistance of *A. baumannii* in Iran.

2. Materials and methods

2.1. Database searches

Biomedical databases (Scopus, Medline, Web of Science, EBSCO, IranMedex) were searched in order to retrieve all related manuscripts published in English and Persian. The search identified publications of epidemiological studies in order to compile adequate information on *A. baumannii* antimicrobial resistance in Iran. The following key words were used: “Acinetobacter baumannii and Iran”, “antimicrobial resistance and *Acinetobacter baumannii* and Iran”, “antimicrobial resistance and either gram negative bacilli and Iran or Iran”, “nosocomial or hospital acquired and Iran”. Study publications were obtained through PubMed, MEDLINE, and IranMedex database searches. Also, references cited within these articles were used to find additional relevant articles. In this review, *A. baumannii* susceptibility breakpoints based on Clinical Laboratory Standards Institute (CLSI)-relevant antibiotics were primarily those listed by the World Health Organization Recommended Surveillance Standards.

2.2. Study settings

From the first 87 papers, we identified a total of 36 that were written in English and considered to be eligible for inclusion in this review. The selected papers were published between 2008 and September 2014. We categorized studies on the basis of sample collection year, between 2001 and 2013; some papers collect samples during different years (Table 1). Two studies were performed in three regions of Iran, including central, north, and south. Twenty-two studies were performed north of Iran, with 18 in Tehran (capital of Iran). Two studies occurred in the south of Iran, three in the west, and three in the east. Although the studies used various methods, they were all approved by the CLSI and the National Committee for Clinical Laboratory Standards (NCCLS) and, therefore, suitable for trend analysis.

2.3. Microbiological methods

Clinical specimens in studies were collected from hospitalized patients with different disease and various sampling. Twenty of the studies obtained data from various clinical specimens, including blood, cerebrospinal fluid, urine, sputum, and respiratory tract samples. Data from eight studies were obtained from patients with burn wounds and seven from hospitalized patients in ICUs. Antibiotic susceptibility testing methodologies were declared in all studies, all of which were performed according to the CLSI breakpoints. Twenty-six studies used the Kirby-Bauer disk diffusion method, nine used the E-test, and two used broth microdilution. To identify resistance genes, 25 of the studies used one or more polymerase chain reaction-based molecular methods.

3. Results

3.1. Phenotypic resistance rates for different antibiotics

The susceptibility data for 3049 *A. baumannii* isolates are shown in Table 2. These data reflect the 12-year period from 2001 to 2013 of sampling time in the studies identified. The data demonstrate that, with the exception of carbapenems, lipopeptides, and aminoglycosides, there was a high rate of resistance to antimicrobial groups during the initial time point of this study (2001–2007). Also, the resistance rate was increased in one group of these three antimicrobial groups from 2010 to 2013. In particular, there was an increase in resistance to carbapenems (imipenem and meropenem) from 2010–2011 and 2012–2013, whereas no significant
change in the resistance rate to other two antimicrobial groups (lipopeptides and aminoglycosides) during the study time was observed, although we did observe certain trends in amikacin (aminoglycoside group antibiotic) between 2011–2012 and 2012–2013.

There are data regarding resistance to penicillins from 2001 to 2011. There was a remarkable increase in piperacillin resistance (from 63.9% in 2001 to 2002). Over the study period, there was noted among the cephems (β-lactamase combination group) was high early in the study, with no substantial change to the study endpoint. The highest level of antimicrobial resistance throughout the study was noted among the cephems group (>90%), including ceftazidime, cefepime, cefotaxime, and ceftriaxone. Resistance to carbapenems was low at the study start point (51.1% imipenem, 64.3% meropenem) and increased by the end of the study (76.5% imipenem, 81.5% meropenem), thus demonstrating the most drastic increase in resistance rate. A low level of resistance at the starting point was also observed for lipopeptides (polymyxin B and colistin), with no significant trends as the study progressed. The resistance rate to aminoglycosides was low, with the exception of amikacin (from 58.4% in 2001 to 2012) and 93.4% in 2010. The resistance rate to the β-lactam/β-lactamase combination group was highest early in the study period with no remarkable pattern change.

3.3. Distribution of multidrug resistance

By definition, MDR *A. baumannii* isolates are resistant to three or more agents of different antibiotic classes. In total, seven studies revealed the presence of MDR isolates. Among these seven studies, this analyzed 584 *A. baumannii* isolates, MDR rates ranged from 32.7% to 93%. Chronologically, these rates can be broken down as follows: 2001–2007 (1 study, 50%), 2008–2009 (1 study, 66%), 2009–2010 (1 study, 83%), and 2010–2011 (4 studies, 32.7%, 74.9%, 93%, 94.4%, respectively). In general, the prevalence of MDR increased throughout the duration of the study.

4. Discussion

*A. baumannii* infection has become a critical challenge to health care systems. To become an optimally successful pathogen, an organism must develop antimicrobial resistance. Although there is debate regarding the definitions of “multidrug” and “pandrug” resistance [45], an understanding has been reached in that resistance to all common antimicrobial agents is currently a common problem in health care institutions [46,47]. The emergence of MDR isolates has become a serious problem that has made it difficult to select an empirical antimicrobial for the treatment of *A. baumannii* infections. Therefore, monitoring the antibiotic resistance

### Table 1. Characteristic of *Acinetobacter baumannii* antimicrobial resistance studies in Iran.

| Year of sample collecting | No. of studies | Total samples | Location of Iran (No. of studies) |
|---------------------------|---------------|---------------|----------------------------------|
| 2008 [10], 2010 [11], 2011 [12], 2014 [13] | 2001–2007 | 4 | 383 | Capital (4) |
| 2011 [14], 2011 [15] | 2007–2008 | 2 | 275 | Capital (1), South (1) |
| 2010 [16], 2010 [17], 2011 [14], 2011 [18], 2011 [19], 2012 [20], 2013 [21] | 2008–2009 | 8 | 680 | Capital (1), North (3), West (2), South (1), East (1) |
| 2011 [22], 2012 [23], 2013 [24] | 2009–2010 | 3 | 276 | Capital (3) |
| 2012 [25], 2012 [26], 2013 [27], 2013 [28], 2013 [29], 2013 [30], 2013 [31], 2013 [32], 2013 [33], 2013 [34], 2014 [35], 2014 [36], 2014 [37], 2013 [38], 2013 [39], 2014 [13], 2014 [40] | 2010–2011 | 12 | 970 | Capital (6), North (4), East (1), West (1) |
| 2013 [41], 2013 [42], 2014 [43], 2014 [44] | 2011–2012 | 6 | 525 | Capital (5), East (1) |
| 2012–Sep 2014 | 2012–Sep 2014 | 4 | 308 | Capital (3), North (1) |
| Antibiotic agents | 2001–2007  
| n = 383 (4 studies) | 2007–2008  
| n = 275 (2 studies) | 2008–2009  
| n = 620 (7 studies) | 2009–2010  
| n = 276 (3 studies) | 2010–2011  
| n = 907 (12 studies) | 2011–2012  
| n = 280 (4 studies) | 2012–Sep 2014  
| n = 308 (4 studies) |
| PIP | 69.9 | 88.2 | 93.75 | 98 | 93.4 | — | — |
| MZ | — | — | — | — | 81.7 | — | — |
| TIC | 100 | — | 100 | — | 94 | — | — |
| SAM | 83.3 | 27.8 | 63.5 | 48.39 | 33.7 | — | 77.5 |
| TZP | 52.9 | 35.3 | 88.6 | 71.5 | 97.3 | 82.5 | 70 |
| TIM | 100 | — | 82.6 | — | 94 | 80 | — |
| CAZ | 93.5 | 90.7 | 92 | 93 | 92.6 | — | 97 |
| FEP | — | 94.1 | 89 | 96.6 | 88.6 | — | 97 |
| CTX | 95 | 100 | 94 | 99 | 96.1 | 98 | 97 |
| CRO | 89.1 | 100 | 93.6 | 97.3 | 95.6 | — | 97.5 |
| IPM | 51.1 | 32 | 57.75 | 52.4 | 81.9 | 80.5 | 76.5 |
| MEM | 64.3 | 27.8 | 59.25 | 72 | 85.2 | 81.5 | 81.5 |
| PB | 8.8 | — | 16 | 3 | 13.5 | 3 | 9.5 |
| CST | — | 1.3 | 19 | 12 | 9.3 | — | 16 |
| GEN | 76.85 | 81.9 | 83.75 | 40.9 | 82.9 | 63 | 78.5 |
| TOB | 63.2 | 39.2 | 28 | 60.9 | 56 | 70 |
| AMK | 58.4 | 79.4 | 82.7 | 69.5 | 75 | 89.5 | 95 |
| NET | 80.5 | — | — | — | 69.6 | — | — |
| TET | — | — | 34.78 | 83.82 | 51 | 56 |
| DOX | — | — | — | 25 | — | — | 42.9 |
| MIN | — | — | — | — | 25.6 | — | 34 |
| CIP | 83.9 | 67.6 | 83.75 | 92 | 85.2 | 97 | 72 |
| LVX | 83.3 | — | 81.75 | — | 81.25 | — | 99 |
| GAT | — | — | — | — | 43.3 | — | — |
| SXT | 76.6 | 82.4 | 87.3 | — | 94.3 | — | 99 |

AMK = amikacin; CAZ = ceftazidime; CIP = ciprofloxacin; CRO = ceftriaxone; CST = colistin; CTX = cefotaxime; DOX = doxycycline; FEP = cefepime; GAT = gatifloxacin; GEN = gentamicin; IPM = imipenem; LVX = levofloxacin; MEM = meropenem; MIN = minocycline; MZ = mezlocillin; NET = netilmicin; PB = polymyxin B; PIP = piperacillin; SAM = ampicillin/sulbactam; SXT = trimethoprim/sulfamethoxazole; TET = tetracycline; TIC = ticarcillin; TIM = ticarcillin/clavulanic acid; TOB = tobramycin; TZP = piperacillin/tazobactam.
Table 3. Genotypic resistance rate in *Acinetobacter baumannii* isolate from Iran.

| Antimicrobial class | Resistance mechanism | Genes | Mean Resistance rate (%) in different studies |
|---------------------|----------------------|-------|-----------------------------------------------|
|                     |                      |       | 2001—2007 | 2007—2008 | 2008—2009 | 2009—2010 | 2010—2011 | 2011—2012 | 2012—Sep 2014 | References |
| β-lactams           | β-lactamases         | PER-1 | 51 | 54.3 | 27.6 | 78.03 | 21,27,23,45 |
|                     |                      | PER-2 | 0 | | | | 21 |
|                     |                      | VEB-1 | 10 | | | | |
|                     |                      | TEM-1 | 47.2 | 13.1 | | | 23,27 |
|                     |                      | SHV   | 5.6 | | | | 27 |
|                     |                      | ISAba1/ampC | 46 | | 63.1 | | 23,27,20 |
|                     |                      | ISAba25/ampC | 7.8 | | | | 27 |
| Carbapenemases      | OXA-23 -like         | 25, | 55 | 24.58,84 | 30,67,77.9,80 | 70.1 | 28,30,27,23,20,22,12,37,44 |
|                     | OXA-48 -like         | | 17.1,47 | | | 35.8 | 28,27,44 |
|                     | OXA-58 -like         | 21.2 | | | | | 12 |
|                     | OXA-24 -like         | 15, | | | | | 12,34 |
|                     | OXA-51 -like         | 96 | | 94 | 14.4 | | 28,22,10 |
|                     | IMP                  | 19 | | | | 3.48 | 18,45 |
|                     | VIM                  | 9 | | | | 17.44 | 18,45 |
| Tetracyclines       | Tet A                | | | | | | |
|                     | Tet B                | | 99,86.1 | | 19.4 | | 36,37,44 |
| Aminoglycosides     | Enzymatic degradation | aph(3')-Ilb | 61.8 | | | | 29 |
|                     |                      | aac(6')-Ib | 60.5 | | 16.4 | | 29,44 |
|                     |                      | aph(3')-Ia | 46.1 | | 19.4 | | 29,44 |
|                     |                      | ant(2')-Ia | 14.5 | | 56.7 | | 29,44 |
|                     |                      | ant(3')-Ia | 10.5 | | | | 29 |
|                     |                      | aph(3')-Via | 9.2, | 95.5 | | | 29,44 |
|                     |                      | aac(3')-Ia | 5.3 | | | | 29,44 |
|                     |                      | aacC1 | 63.3 | | | | 16 |
|                     |                      | aadA1 | 41.7 | | | | 16 |
|                     |                      | aadB | 3.3 | | | | 16 |
|                     |                      | aphA6 | 65 | | | | 16 |
|                     |                      | armA | 9 | | | | 44 |
| Quinolones          | DNA methyltransferases | gyrA/parC | 100 | | | | 37 |

Antimicrobial Resistance in *Acinetobacter baumannii* from Iran.
patterns of this organism over time may provide useful information regarding its treatment policy. This systematic review considered the distribution of antibiotic-resistant *A. baumannii* in CLSI-approved studies published in Iran between 2001 and September 2014.

According to the results, some level of resistance to all antibiotic classes existed in the beginning of our study. However, we revealed that the distribution of antimicrobial resistance to all agents was high at the endpoint, with the exception of the lipopeptides. Currently, the antibiotics of choice for treatment of *A. baumannii* infections include the aminoglycosides, fluoroquinolones, and carbapenems [48]. Thus, it is concerning that our data demonstrate that *A. baumannii* resistance to these agents increased over the time course of this study, with a resistance rate in excess of 90% in 2013. As such, these antibiotics may not be appropriate empirical therapy in many cases. For example, carbapenems are one of the most clinically important classes of antibiotics used against life-threatening *A. baumannii* infections in Iran [10]. Our results showed that this group of antibiotics had low-level resistance in 2001—2007 (51.1% imipenem, 64.3% meropenem), which increased in 2012—2013 (76.5% imipenem, 81.5% meropenem). The data also showed that the most drastic increase in resistance is associated with this antibiotic class, possibly due to its frequency of use in health care units. This is an alarming finding that strongly suggests the possibility of treatment failures in life-threatening *A. baumannii* infections due to carbapenem-resistance strains.

As mentioned previously, our data show that resistance to lipopeptides is lower compared with that of other antimicrobial groups. One of the antibiotics of this class is polymyxin B, which, despite previous concerns regarding its toxicity, has been implemented in treatment more frequently [49]. Another lipopeptide antibiotic is colistin, which has proven effective in the treatment of wound, urinary tract, and bloodstream infections [50], although its nephrotoxicity is a disadvantage to its use [51]. Although use of this antibiotic class has limitations due to toxicity, they are often used for the treatment of life-threatening infections.

In addition to an increase in antibiotic-resistant *A. baumannii* strains from 2001 to 2013, the prevalence of MDR strains also increased (from 50% in 2001—2007 to 74% in 2010—2011), with a mean prevalence of 71.2%. Treatment of MDR strains is usually difficult, thus creating critical challenges for health care consultants [52,53]. The antibiotic choice for the treatment of MDR *A. baumannii* infections is also limited and includes the lipopeptides, [52,54] which the results of this study suggest is the best class of antibiotics to use for MDR because of the lower prevalence of resistance.

In summary, our results demonstrate the need for effective surveillance of antimicrobial resistance in *A. baumannii* in Iran and suggest that it is essential to use antibiotics with the most caution to prevent the emergence of drug-resistant strains. Furthermore, these findings indicate that the prevalence of antibiotic-resistant *A. baumannii* is high in Iran, especially for the antibiotics of choice. This is an emerging concern to public health, particularly in the clinical management of persons with life-threatening *A. baumannii* infections. We strongly suggest the implementation of a country-wide surveillance system. This would facilitate the active monitoring of resistance frequency and distinguish antibiotic resistance trends and prevalence, all of which would be effective tools in antibiotic treatment programs.

### Conflicts of interest

None to declare.

### References

1. Chittawatanarit K, Jaipakdee W, Chotirosniramit N, et al. Microbiology, resistance patterns, and risk factors of mortality in ventilator-associated bacterial pneumonia in a Northern Thai tertiary-care university based general surgical intensive care unit. Infect Drug Resist 2014;7:203—10.

2. Eveillard M, Kempf M, Belmonte O, et al. Reservoirs of *Acinetobacter baumannii* outside the hospital and potential involvement in emerging human community-acquired infections. Int J Infect Dis 2013;17(10):802—5.

3. Oh YJ, Song SH, Baik SH, et al. A case of fulminant community-acquired *Acinetobacter baumannii* pneumonia in Korea. Korean J Intern Med 2013;28(4):486—90.

4. Kim UJ, Kim HK, An JH, et al. Update on the epidemiology, treatment, and outcomes of carbapenem-resistant *Acinetobacter baumannii* infections. Chonnam Med J 2014 Aug;50(2):37—44.

5. Tang SS, Apisarnthanarak A, Hsu LY. Mechanisms of β-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria. Adv Drug Deliv Rev 2014 Nov;78:3—13.

6. Nhu NT, Lan NP, Campbell JL, et al. Emergence of carbapenem-resistant *Acinetobacter baumannii* as the major cause of ventilator-associated pneumonia in intensive care unit patients at an infectious disease hospital in southern Vietnam. J Med Microbiol 2014 Oct;63(10):1386—94.

7. Liu B, Liu Y, Di X, et al. Colistin and anti-Gram-positive bacterial agents against *Acinetobacter baumannii*. Rev Soc Bras Med Trop 2014 Jul;47(4):451—6.

8. García-Quintanilla M, Pulido MR, López-Rojas R, et al. Emerging therapies for multidrug resistant *Acinetobacter baumannii*. Trends Microbiol 2013;21:157—63.

9. Antunes LC, Visca P, Towner KJ. *Acinetobacter baumannii*: evolution of a global pathogen. Pathog Dis 2014 Aug;71(3):292—301.

10. Feizabadi MM, Fathollahzadeh B, Taherikalani M, et al. Anti-microbial susceptibility patterns and distribution of blaOXA genes among *Acinetobacter* spp. Isolated from patients at Tehran hospitals. Jpn J Infect Dis 2008;61:274—8.

11. Soroush S, Haghi-Ashitian MT, Taheri-Kalani M, et al. Anti-microbial resistance of nosocomial strain of *Acinetobacter baumannii* in Children’s Medical Center of Tehran: a 6-year prospective study. Acta Med Iranica 2010;48:178—84.

12. Taherikalani M, Maleki A, Sadeghifard N, et al. Dissemination of class 1, 2 and 3 integrons among different multidrug resistant
isolates of *Acinetobacter baumannii* in Tehran hospitals, Iran. Pol J Microbiol 2011;60(2):169–74.

13. Bahador A, Raoofian R, Taheri M, et al. Multidrug resistance among Acinetobacter Baumannii isolates from Iran: Changes in antimicrobial susceptibility patterns and genotypic profile. Microb Drug Resit 2014 Dec;20(6):632–40.

14. Japoni-Nejad A, Farshad S, et al. Association between existence of integrons and multi-drug resistance in Acinetobacter isolated from patients in southern Iran. Pol J Microbiol 2011;60(2):163–8.

15. Mohammadi-Mehr M, Feizabadi MM. Antimicrobial resistance pattern of Gram-negative bacilli isolated from patients at ICUs of Army hospitals in Iran. Iran J Microbiol 2011;3:26–30.

16. Moniri R, Farahani RK, Shajari G, et al. Molecular epidemiology of aminoglycosides resistance in Acinetobacter spp. With emergence of multidrug-resistant strains. Iran J Public Health 2010;39(2):63–8.

17. Sarafzadeh F, Sohrevardi S, Ghareghozhi M, et al. Detection of the most common microorganisms and their resistance against anti-microbials in intubated patients in an ICU in Kerman, Iran. Iran J Respir Dis 2010 Fall;9(4):43–7.

18. Peymani A, Nahaei MR, Farajnia S, et al. High prevalence of metallo-beta-lactamase-producing *Acinetobacter baumannii* in a teaching hospital in Tabriz. Iran J Infect Dis 2011;64:69–74.

19. Peymani A, Farajnia S, Nahaei MR, et al. Prevalence of class 1 integron among multidrug-resistant *Acinetobacter baumannii* in Tabriz, northwest of Iran. Pol J Microbiol 2012;61:57–60.

20. Sohrabi N, Farajnia S, Akhi MT, et al. Prevalence of OXA-type beta-lactamasms among *Acinetobacter baumannii* isolates from Northwest of Iran. Microb Drug Resist 2012;18(1):385–9.

21. Farajnia S, Azhari F, Alilkhani MY, et al. Prevalence of PER and VEB type extended spectrum beta-lactamasms among multidrug resistant *Acinetobacter baumannii* isolates in North-West of Iran. Iran J Basic Med Sci 2013 Jun;16:751–5.

22. Shahcheraghi F, Abbasalipour M, Feizabadi MM, et al. Isolation and genetic characterization of metallo-beta-lactamase and carbapenemase producing strains of *Acinetobacter baumannii* from patients at Tehran hospitals. Iran J Microbiol 2011 June;3(2):68–74.

23. Asadollahi P, Akbari M, Soroush S, et al. Antimicrobial resistance patterns and their encoding genes among *Acinetobacter baumannii* strains isolated from burned patients. Burns 2012 Dec;38(8):1198–203.

24. Mirnejad R, Mostofi S, Masjedian F. Antibiotic resistance and carriage class 1 and 2 integrons in clinical isolates of *Acinetobacter baumannii* from Tehran, Iran. Asian Pac J Trop Biomed 2013 Apr;3(2):140–8.

25. Owlia P, Azimi L, Gholami A, et al. ESBL- and MBL-mediated beta-lactamases producer *Acinetobacter baumannii* from central Iran. Int J Med Microbiol 2013 Dec;397(9):2383–7.

26. Maleki MH, Sekawi Z, Soroush S, et al. Phenotypic and genotypic characteristics of tetracycline resistant *Acinetobacter baumannii* isolates from nosocomial infections at Tehran hospitals. Iran J Basic Med Sci 2014 Jan;17(1):21–6.

27. Nowroozi J, Sepahi AA, Kamarpooishi LT, et al. Evaluation of ciprofloxacin (gvaA, parc genes) and tetracycline (tetB gene) resistance in nosocomial *Acinetobacter baumannii* infections. Jundishapur J Microbiol 2014 Feb;7(2):e8976.

28. Mirnejad R, Vaefai S. Antibiotic resistance patterns and the prevalence of ESBLs among strains of *Acinetobacter baumannii* isolated from clinical specimens. JGMI 2013;2:1–8.

29. Safari M, Saidijam M, Bahador A, et al. High prevalence of multidrug resistance and metallo-beta-lactamase (MbetaL) producing *Acinetobacter baumannii* isolated from patients in military wards, Hamadan. Iran J Res Health Sci 2013 Sep;13(2):162–7.

30. Vakili B, Fazeli H, Shoaei P, et al. Detection of colistin sensitivity in clinical isolates of *Acinetobacter baumannii* in Iran. Iran J Res Med Sci 2014 Mar;19(Suppl. 1):S67–70.

31. Bahador A, Taheri M, Pourakbari B, et al. Emergence of rifampicin, tigecycline, and colistin-resistant *Acinetobacter baumannii* in Iran; spreading of multidrug-resistant (MDR) strains of novel International Clone variants. Microb Drug Resist 2013 Oct;19(5):397–406.

32. Kamalbeik S, Talaie H, Mahdavinejad A, et al. Multidrug-resistant *Acinetobacter baumannii* infection in intensive care unit patients in a hospital with building construction: is there an association? Korean J Anesthesiol 2014 Apr;66(4):295–9.

33. Pajand O, Hojabri Z, Nahaei MR, et al. In vitro activities of tetracyclines against different clones of multidrug-resistant *Acinetobacter baumannii* isolates from two Iranian hospitals. Int J Antimicrob Agents 2014 May;43(5):476–8.

34. Fallah F, Noori M, Hashemi A, et al. Prevalence of bla NDM, bla PER, bla VEB, bla IMP, and bla VIM genes among *Acinetobacter baumannii* isolated from two hospitals of Tehran, Iran. Iran J Med Sci 2013 Mar;38(1):15–20.

35. Hoebeke P, Van Belkum A, et al. carriage class 1 and 2 integrons in clinical isolates of *Acinetobacter baumannii*. Diagn Microb Dis 2013 Jul;67(3):330–4.

36. Pajand O, Rezaee MA, Nahaei MR, et al. Prevalence of Ambler class a beta-lactamases and ampC expression in chloramphenicol-resistant isolates of *Acinetobacter baumannii*. Diagn Microb Dis 2013 Jul;67(3):330–4.

37. Rezaee MA, Pajand O, Nahaei MR, et al. Prevalence of Ambler class a beta-lactamases and ampC expression in chloramphenicol-resistant isolates of *Acinetobacter baumannii*. Diagn Microb Dis 2013 Jul;67(3):330–4.

38. Pajand O, Rezaee MA, Nahaei MR, et al. Study of the carbapenem resistance mechanisms in clinical isolates of *Acinetobacter baumannii*: comparison of burn and non-burn strains. Burns 2013 Nov;39(7):1414–9.

39. Aghazadeh M, Rezaee MA, Nahaei MR, et al. Dissemination of aminoglycoside-modifying enzymes and 16S rRNA methylation among *Acinetobacter baumannii* and *Pseudomonas aeruginosa* isolates. Microb Drug Resist 2013 Aug;19(4):282–8.

40. Azimi L, Lari AR, Talebi M, et al. Comparison between phenotypic and PCR for detection of OXA-23 type and metallo-beta-lactamasms producer *Acinetobacter baumannii* spp. GMS Hyg Infect Control 2013 Nov;8(2):16.

41. Japoni-Nejad A, Sohan M, Belkum A, et al. Nosocomial outbreak of extensively and pan drug-resistant *Acinetobacter baumannii* in tertiary hospital in central part of Iran. Jundishapur J Microbiol 2013;6:92–8.

42. Japoni-Nejad A, Farshad S, van Belkum A, et al. Novel cassette array in a class 1 integron in clinical isolates of *Acinetobacter baumannii* from central Iran. Int J Med Microbiol 2013 Dec;303(8):645–50.

43. Karmoostaji A, Peerayeh SN, Salmanian AH. Distribution of OXA-type class D β-lactamases genes among nosocomial multi drug resistant *Acinetobacter baumannii* isolated in Tehran Hospital. Jundishapur J Microbiol 2013;6:12–4.

44. Mohajeri P, Farahani A, Feizabadi MM, et al. Antimicrobial susceptibility profiling and genomic diversity of *Acinetobacter baumannii* isolates: A study in western Iran. Iran J Microbiol 2013 Sep;5(3):195–202.

45. Hojabri Z, Pajand O, Bonura C, et al. Molecular epidemiology of *Acinetobacter baumannii* in Iran: endemic and epidemic spread of multiresistant isolates. J Antimicrob Chemother 2014 Sep;69(9):2383–7.

46. Maleki MH, Sekawi Z, Soroush S, et al. Phenotypic and genotypic characteristics of tetracycline resistant *Acinetobacter baumannii* isolates from nosocomial infections at Tehran hospitals. Iran J Basic Med Sci 2014 Jan;17(1):21–6.

47. Nowroozi J, Sepahi AA, Kamarpooishi LT, et al. Evaluation of ciprofloxacin (gvaA, parc genes) and tetracycline (tetB gene) resistance in nosocomial *Acinetobacter baumannii* infections. Jundishapur J Microbiol 2014 Feb;7(2):e8976.

48. Mirnejad R, Vaefai S. Antibiotic resistance patterns and the prevalence of ESBLs among strains of *Acinetobacter baumannii* isolated from clinical specimens. JGMI 2013;2:1–8.

49. Safari M, Saidijam M, Bahador A, et al. High prevalence of multidrug resistance and metallo-beta-lactamase (MbetaL) producing *Acinetobacter baumannii* isolated from patients in military wards, Hamadan. Iran J Res Health Sci 2013 Sep;13(2):162–7.

50. Vakili B, Fazeli H, Shoaei P, et al. Detection of colistin sensitivity in clinical isolates of *Acinetobacter baumannii* in Iran. Iran J Res Med Sci 2014 Mar;19(Suppl. 1):S67–70.
into the epidemic. Infect Control Hosp Epidemiol 2009 Feb;30(2):196–7.

48. Dijkshoorn L, Aucken H, Gerner-Smidt P, et al. Comparison of outbreak and nonoutbreak Acinetobacter baumannii strains by genotypic and phenotypic methods. J Clin Microbiol 1996 Jun;34(6):1519–25.

49. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005 May;40(9):1333–41.

50. Gounden R, Bamford C, van Zyl-Smit R, et al. Safety and effectiveness of colistin compared with tobramycin for multidrug-resistant Acinetobacter baumannii infections. BMC Infect Dis 2009 Mar;9(9):26–8.

51. Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 2006 Sep;21(Suppl. 2):89–94.

52. Fishbain J, Peleg AY. Treatment of Acinetobacter infections. Clin Infect Dis 2010 Jul;51(1):79–84.

53. Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis 2010;23:332–9.

54. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008 Jul;21(3):538–82.